We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluating the Effect of Aliskiren Versus HCTZ on Coronary Flow Reserve in Hypertensive Type II Diabetics

This study has been withdrawn prior to enrollment.
(Due to safety concerns re: the concomitant use of aliskiren with an ACEi or ARB.)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00994253
First Posted: October 14, 2009
Last Update Posted: October 2, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Pam Marcovitz, MD, William Beaumont Hospitals
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Estimated Study Completion Date: December 2012
  Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)